| JPM THEMATICS-GENETIC THERAPIES A (ACC) USD | RVI BIOTECNOLOGÍA | 39,77% | 15,80% | -22,24% | · |
| COMGEST GROWTH JAPAN EUR R H ACC | RVI JAPÓN CRECIMIENTO | 39,76% | 84,21% | 68,28% | · |
| CPR INVEST GLOBAL RESOURCES A USD ACC | RVI MATERIAS PRIMAS | 39,76% | 42,09% | 73,47% | · |
| UBS BBG COMMODITY INDEX SF UCITS ETF USD ACC | RVI MATERIAS PRIMAS | 39,76% | · | · | · |
| NOMURA FUNDS IRELAND - JAPAN STRATEGIC VALUE FUND R USD HEDGED | RVI JAPÓN VALOR | 39,74% | 112,85% | 187,83% | 204,22% |
| UBS (LUX) EQUITY SICAV - GLOBAL HIGH DIVIDEND (USD) Q-ACC | RVI GLOBAL VALOR | 39,74% | 68,01% | 93,41% | 167,25% |
| AZVALOR LUX SICAV - AZVALOR INTERNATIONAL-R | RVI GLOBAL | 39,73% | 39,70% | 115,12% | · |
| CAIXABANK MASTER RENTA VARIABLE ESPAÑA, FI | RV ESPAÑA | 39,73% | 125,48% | 164,14% | · |
| EDMOND DE ROTHSCHILD FUND-STRATEGIC EMERGING A USD CAP | RVI EMERGENTES | 39,72% | 61,37% | 25,92% | 65,15% |
| CAIXABANK BOLSA GESTION ESPAÑA, FI PLUS | RV ESPAÑA | 39,71% | 128,04% | 150,43% | 245,70% |
| POLAR CAPITAL ASIAN STARS S USD CAP | RVI ASIA PACÍFICO | 39,71% | 66,78% | 47,72% | · |
| SCHRODER ISF QEP EMERGING MARKETS CORE I ACC EUR | RVI EMERGENTES VALOR | 39,71% | 72,02% | 55,02% | · |
| GOLDMAN SACHS EMERGING MARKETS EQUITY PORTFOLIO I USD DIS | RVI EMERGENTES | 39,70% | 63,06% | 25,80% | 117,91% |
| JPM THEMATICS-GENETIC THERAPIES A (DIST) USD | RVI BIOTECNOLOGÍA | 39,70% | 15,56% | -22,56% | · |
| JPM THEMATICS-GENETIC THERAPIES C (DIST) USD | RVI BIOTECNOLOGÍA | 39,70% | 16,18% | -21,45% | · |
| DWS INVEST ESG EMERGING MARKETS TOP DIVIDEND LD | RVI EMERGENTES VALOR | 39,69% | 56,19% | 33,31% | 44,20% |
| CT (LUX) RESPONSIBLE GLOBAL EMERGING MARKETS EQUITY R CHF ACC | RVI EMERGENTES | 39,68% | 58,83% | 42,60% | · |
| AMUNDI MSCI EM ASIA UCITS ETF EUR CAP | RVI ASIA PACÍFICO | 39,67% | 70,89% | 57,02% | · |
| GOLDMAN SACHS EMERGING MARKETS EQUITY PORTFOLIO R USD DIS | RVI EMERGENTES | 39,67% | 63,11% | 25,83% | 118,19% |
| GOLDMAN SACHS EMERGING MARKETS EQUITY PORTFOLIO OTHER CURRENCY EUR CAP | RVI EMERGENTES | 39,65% | 61,64% | 24,91% | 113,43% |
